Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-Line XELOX Plus Anlotinib Hydrochloride Followed by Single-Agent Anlotinib Hydrochloride as Maintenance Therapy in Patients with Metastatic Colorectal Carcinoma: An Open, Single Arm, Multicenter, Exploratory Clinical Trial

Next Previous
Trial Profile

First-Line XELOX Plus Anlotinib Hydrochloride Followed by Single-Agent Anlotinib Hydrochloride as Maintenance Therapy in Patients with Metastatic Colorectal Carcinoma: An Open, Single Arm, Multicenter, Exploratory Clinical Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms ALTER-C-001

Most Recent Events

  • 21 Jan 2023 Results (at data cut-off: 30 June 2022; n=31) assessing efficacy and safety at a longer follow-up were presented at the 2023 Gastrointestinal Cancers Symposium.
  • 13 Sep 2022 Updated Results(n=31, At data cut-off April 22, 2022) assessing Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with metastatic colorectal cancer presented at the 47th European Society for Medical Oncology Congress
  • 07 Jun 2022 Update results (n=29) presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top